menu search

Travere therapeutics announces late-breaking data from phase 3 studies of sparsentan in igan and fsgs published in the lancet and the nejm respectively and presented at the american society of nephrol

Two-year results from both PROTECT and DUPLEX pivotal Phase 3 studies demonstrate treatment with sparsentan has the potential to preserve kidney ...

November 3, 2023, 2:46 pm

Fp markets launches new look client portal with an array of enhanced features

FP Markets, a leading broker in online trading for Forex and CFDs, has announced the launch of its redesigned Client Portal. This transformative upgra...

November 3, 2023, 1:49 pm

Futura medical wins new product award from boots

Futura Medical's Eroxon erectile dysfunction treatment won the "New Product of the Year, Healthcare" c...

November 2, 2023, 12:15 pm

Are kyc and aml protocols enough to curb fraud?

The fight against fraud is an ongoing one. Financial institutions must rely on strong measures to secure their operations and consumers as technology ...

November 2, 2023, 10:40 am

Warm farewell given to cad official

Subject Matter Specialist-DL at Project Office, Command Area Development Jammu, Manoj Kumar Pandoh, who got retired after rendering 36 years of his se...

November 1, 2023, 11:14 pm

B2core’s brand-new ios v1.20 upgrade integrates ctrader and polishes the ux

B2Core is an established name in the forex and crypto trading field, delivering CRM tools and trading options with unmatched quality and depth of ...

November 1, 2023, 1:00 pm

News nuggets | 1 november: b2core adds ctrader; cftc pays this year mostly for crypto tips

B2Core Releases New iOS Update Featuring cTrader IntegrationB2Core has released a new iOS update that integrates the cTrader trading software, aiming ...

November 1, 2023, 11:27 am

Springworks therapeutics announces presentation of additional data from phase 3 defi trial of nirogacestat in adults with desmoid tumors at the 2023 ctos annual meeting

– Nirogacestat Treatment Demonstrated Rapid and Sustained Improvements in functional Status Compared ...

November 1, 2023, 10:30 am

Zymeworks announces participation in upcoming investor conferences

VANCOUVER, British Columbia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel,...

November 1, 2023, 8:30 am

Eyemd emr healthcare systems inc. announces the release of axon patient engagement at aao 2023

BONITA SPRINGS, Fla., Oct. 31, 2023 (GLOBE NEWSWIRE) — EyeMD EMR, a leading provider of clinical software solutions designed specifically for eye ca...

October 31, 2023, 1:55 pm

Finalto expands offering to include precious metals fixing

Finalto, is excited to announce the introduction of metals fixing, specifically for gold and silver, to its already comprehensive suite of financial s...

October 31, 2023, 9:05 am

What are the functions of the secondary market?

What are the functions of the secondary market? Key takeaways: Significance: The secondary market is cr...

October 30, 2023, 1:48 pm

Novartis says drug candidate is successful in rare kidney disease trial

Novartis said its experimental drug atrasentan was shown to have a positive effect on kidney function i...

October 30, 2023, 3:42 am

Is the us insurance system broken and can insurtech save it?

The United States has a big and complicated insurance system that plays an important role in protecting individuals and businesses against a variety o...

October 27, 2023, 5:02 pm

Cognyte software sees margin improvement as revenue ticks up

Cognyte Software Ltd. provides security analytics and software functionalities to governments and organ...

October 27, 2023, 10:43 am

Microsoft earnings review: bing is changing the game

Microsoft's search momentum is outpacing Google, with Bing gaining share for the tenth consecutive quarter. Bing's integration of generative AI and ch...

October 27, 2023, 4:13 am

Eisai presents new leqembi® (lecanemab-irmb) investigational subcutaneous formulation interim study results and clinical improvement data in earlier stages of early alzheimer’s disease from additional

Investigational Subcutaneous Formulation Clears 14% More Plaque Than IV, Pharmacokinetics (AUC) 11% Higher, And Similar ARIA Rates To IV 76% Of Patien...

October 25, 2023, 9:26 pm

Eisai presents new leqembi® (lecanemab-irmb) investigational subcutaneous formulation interim study results and clinical improvement data in earlier stages of early alzheimer’s disease from additional

Investigational Subcutaneous Formulation Clears 14% More Plaque Than IV, Pharmacokinetics (AUC) 11% Higher, And Similar ARIA Rates To IV 76% Of Patien...

October 25, 2023, 9:26 pm

Scholar rock: sma data readout in 2024 makes this worth a look

The Scholar Rock Holding Corporation phase 3 SAPPHIRE study for apitegromab for the treatment of type 2 and type 2 SMA patients has completed enrollme...

October 25, 2023, 5:44 pm

New data from biogen’s investigational antisense oligonucleotide (aso) targeting tau shows promise for potential new generation of treatments in early alzheimer’s disease

In the Phase 1b study, favorable trends were reported for the high-dose groups on multiple measures of cognition and ...

October 25, 2023, 2:51 pm


Search within

Pages Search Results: